Navigation Links
TGen partner, PBS-Bio, makes first breakthrough drug analysis

PHOENIX, Ariz. June 18, 2010 Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

PharmaGap is an early-stage biotech company based in Ottawa, Ontario developing novel peptide compounds for cancer. Its lead compound, GAP-107B8, exhibits potent cytotoxic characteristics against cancer cells and has recently completed screening at the National Cancer Institute in Bethesda, Md., and was the subject of a data poster by researchers at the Ottawa Hospital Research Institute at the recent American Association for Cancer Research meeting in Washington, D.C.

Proprietary real-time computer imaging technology from PBS-Bio has been instrumental in assisting PharmaGap to determine the drug's potential mechanism of action and thereby identifying suitable cancers to target for eventual clinical use.

As part of its pre-clinical development program, PharmaGap hired Phoenix-based PBS-Bio to analyze more specifically how the drug worked. PBS-Bio is a privately held, for-profit corporation owned in part by the non-profit Translational Genomics Research Institute (TGen).

Data from the PBS-Bio analysis indicated that GAP-107B8 rapidly compromises the outer membrane of colorectal cancer cells, leading to either oncolytic or apoptotic cell death, while having significantly less affect on non-cancerous cells.

Unlike many protein kinase inhibitor drugs now in development, GAP-107B8 works within mere minutes through "an assault on the plasma membrane," said Dr. Isabella Steffensen, a PharmaGap pre-clinical development consultant. She said that GAP-107B8 appears to be reacting with surface receptors apparently more prevalent on cancer cells than normal cells.

By providing PharmaGap with a more accurate analysis of how the drug functioned, PBS-Bio saved the company months of research and an estimated $400,000 in costs.

Moreover, the PBS-Bio data has assisted PharmaGap to expand the scope of possible cancer targets for GAP-107B8, said Robert McInnis, the company's President and Chief Executive Officer.

McInnis said PharmaGap is now also better positioned with GAP-107B8 to run clinical trials, anticipated in 2012, and expand the scope of its intellectual property and business development potential.

"Based on the insights gleaned from working with the PBS-Bio team in Arizona, we have a much clearer idea of how this compound is acting," McInnis said. "Overall, it was a very successful collaboration. We certainly look forward to a continuing relationship with PBS-Bio"

Like plugging a computer diagnostic into a running car engine, PBS-Bio's technology uses live cancer cells to show pharmaceutical companies how their drugs work, or don't work, said Dr. Michael Bittner, Co-Director of TGen's Computational Biology Division.

"For the first time, we can show at the molecular level exactly how drugs will affect cancer cells in real-time, identifying precisely along which cellular pathways drugs produce results, or fail,'' said Dr. Bittner, who also is a Principal Investigator at TGen for the PBS-Bio technology, and a Member of PBS-Bio's Scientific Advisory Board.

"The success of targeted oncology drugs can vary from tumor to tumor, and the range of the specific types of tumor molecular pathologies that are susceptible or resistant to a given drug are frequently unknown. The purpose of the PBS-Bio technology is to make pre-clinical research more predictive of actual patient outcomes," Dr. Bittner said.

The technology is expected to save pharmaceutical companies millions of dollars in drug development costs, especially by showing what drugs might not work, thereby avoiding costly clinical trials, said Dr. Edward Smith, founder and CEO of PBS-Bio.

The technology also is expected to show which drugs might work better in tandem with other drugs, thereby salvaging promising drug lines that otherwise might be shelved, said Dr. Smith, who also is an adjunct faculty member at TGen and at the University of Arizona College of Medicine.

"Specifically, the TGen-PBS-Bio technology shows, in real time, how drugs affect the genes and their signaling pathways within cells that cause cancers to grow out of control," Dr. Smith said.

The hope is that by using this technology, drug companies will be able to develop cancer drugs more quickly, and at lower costs, while giving researchers a better idea of which patients will best respond to the therapies, Dr. Smith said.

PBS-Bio is working with three large pharmaceutical companies on projects to: determine which of several similar compounds to move into clinical trials, identify which drugs to add to their investigational drug to make it most effective, and identify biomarker tests that will identify patients most likely to respond to the new drug combination.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. After a fight with a partner, brain activity predicts emotional resiliency
2. Life Line Screening Proudly Supports NBC's Skate for the Heart in Honor of Longtime Partner, Peggy Fleming
3. Revolutionary scale makes losing weight easier than ever
4. "How Facebook Makes Lonely People Even Lonelier" Revealed by Distinguished University of Chicago Professor in Interview with Brian Vaszily on
5. Spending time in nature makes people feel more alive, study shows
6. ACR task force makes recommendations for improving relationships between radiologists and hospitals
7. ORCS Web, Inc Makes Available WCF RIA Services
8. Surpasses 100,000 Meal Milestone; Web Site Makes Caring For Friends and Family Easier
9. Fight Obesity with Fitness Entrepreneur's New Product That Makes Inline Skating Safer
10. Safety Training Makes for Safer Mining
11. Wine Enthusiast Facebook Sweepstakes Makes One in Twenty a Winner
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: